A new study in mouse cortical neurons suggests that fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator currently used to treat MS, may reduce beta-amyloid neurotoxicity (Doi et al. PLoS One 2013;8:e6; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC3625222/pdf/pone.0061988.pdf).